A citation-based method for searching scientific literature

Jeffrey A How, Amir A Jazaeri, Bryan Fellman, Molly S Daniels, Suzanna Penn, Cara Solimeno, Ying Yuan, Kathleen Schmeler, Jerry S Lanchbury, Kirsten Timms, Karen H Lu, Melinda S Yates. Cancers (Basel) 2021
Times Cited: 2







List of co-cited articles
10 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
V Abkevich, K M Timms, B T Hennessy, J Potter, M S Carey, L A Meyer, K Smith-McCune, R Broaddus, K H Lu, J Chen,[...]. Br J Cancer 2012
294
100

Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
Hisamitsu Takaya, Hidekatsu Nakai, Shiro Takamatsu, Masaki Mandai, Noriomi Matsumura. Sci Rep 2020
28
100

Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.
Tatiana Popova, Elodie Manié, Guillaume Rieunier, Virginie Caux-Moncoutier, Carole Tirapo, Thierry Dubois, Olivier Delattre, Brigitte Sigal-Zafrani, Marc Bollet, Michel Longy,[...]. Cancer Res 2012
266
100

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
968
100

Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Kirsten M Timms, Victor Abkevich, Elisha Hughes, Chris Neff, Julia Reid, Brian Morris, Saritha Kalva, Jennifer Potter, Thanh V Tran, Jian Chen,[...]. Breast Cancer Res 2014
153
100

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
717
100

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia,[...]. Lancet 2017
575
100

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää,[...]. N Engl J Med 2019
269
100

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
673
100

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer,[...]. N Engl J Med 2019
338
100

The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.
Yakir Segev, Javaid Iqbal, Jan Lubinski, Jacek Gronwald, Henry T Lynch, Pal Moller, Parviz Ghadirian, Barry Rosen, Nadine Tung, Charmaine Kim-Sing,[...]. Gynecol Oncol 2013
62
50


Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy.
Elizabeth Ruth Plummer, Hilary Calvert. Clin Cancer Res 2007
44
50

Inherited Mutations in Women With Ovarian Carcinoma.
Barbara M Norquist, Maria I Harrell, Mark F Brady, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Sarah S Bernards, Silvia Casadei, Qian Yi, Robert A Burger,[...]. JAMA Oncol 2016
335
50

Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany.
Dorothea Gadzicki, D Gareth Evans, Hilary Harris, Claire Julian-Reynier, Irmgard Nippert, Jörg Schmidtke, Aad Tibben, Christi J van Asperen, Brigitte Schlegelberger. J Community Genet 2011
52
50

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mansoor Raza Mirza, Elisabeth Åvall Lundqvist, Michael J Birrer, Rene dePont Christensen, Gitte-Bettina Nyvang, Susanne Malander, Maarit Anttila, Theresa L Werner, Bente Lund, Gabriel Lindahl,[...]. Lancet Oncol 2019
59
50


BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
M Moschetta, A George, S B Kaye, S Banerjee. Ann Oncol 2016
84
50

Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.
C Marchetti, F De Felice, S Boccia, C Sassu, V Di Donato, G Perniola, I Palaia, M Monti, L Muzii, V Tombolini,[...]. Crit Rev Oncol Hematol 2018
25
50

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Susan M Domchek, Tara M Friebel, Christian F Singer, D Gareth Evans, Henry T Lynch, Claudine Isaacs, Judy E Garber, Susan L Neuhausen, Ellen Matloff, Rosalind Eeles,[...]. JAMA 2010
824
50

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Kathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, David Scott Miller, Noelle Cloven, Gini F Fleming, Andrea E Wahner Hendrickson, Masoud Azodi, Paul DiSilvestro, Amit M Oza,[...]. Lancet Oncol 2019
131
50

The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art.
Mike De Vos, Valérie Schreiber, Françoise Dantzer. Biochem Pharmacol 2012
320
50

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. N Engl J Med 2012
50

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2014
841
50

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
Michael Friedlander, Ursula Matulonis, Charlie Gourley, Andreas du Bois, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Br J Cancer 2018
63
50

Assessing the effect of guideline introduction on clinical practice and outcome in patients with endometrial cancer in Japan: a project of the Japan Society of Gynecologic Oncology (JSGO) guideline evaluation committee.
Shogo Shigeta, Satoru Nagase, Mikio Mikami, Masae Ikeda, Masako Shida, Isao Sakaguchi, Norichika Ushioda, Fumiaki Takahashi, Wataru Yamagami, Nobuo Yaegashi,[...]. J Gynecol Oncol 2017
10
50


BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
Marie Soegaard, Susanne Kruger Kjaer, Mark Cox, Eva Wozniak, Estrid Høgdall, Claus Høgdall, Jan Blaakaer, Ian J Jacobs, Simon A Gayther, Susan J Ramus. Clin Cancer Res 2008
72
50

The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE).
Takayuki Enomoto, Daisuke Aoki, Kana Hattori, Masahisa Jinushi, Junzo Kigawa, Nobuhiro Takeshima, Hitoshi Tsuda, Yoh Watanabe, Kosuke Yoshihara, Toru Sugiyama. Int J Gynecol Cancer 2019
31
50

Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort.
Catharina E Jacobi, Yvette van Ierland, Christi J van Asperen, Eric Hallensleben, Peter Devilee, Gert Jan Fleuren, Gemma G Kenter. Genet Med 2007
15
50

Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.
Stefania Gori, Massimo Barberis, Maria Angela Bella, Fiamma Buttitta, Ettore Capoluongo, Paola Carrera, Nicoletta Colombo, Laura Cortesi, Maurizio Genuardi, Massimo Gion,[...]. Crit Rev Oncol Hematol 2019
27
50

Are all pelvic (nonuterine) serous carcinomas of tubal origin?
Christopher G Przybycin, Robert J Kurman, Brigitte M Ronnett, Ie-Ming Shih, Russell Vang. Am J Surg Pathol 2010
298
50

Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.
Sushmita Gordhandas, Barbara M Norquist, Kathryn P Pennington, Rachel L Yung, Mary B Laya, Elizabeth M Swisher. Gynecol Oncol 2019
27
50

Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.
David W Kindelberger, Yonghee Lee, Alexander Miron, Michelle S Hirsch, Colleen Feltmate, Fabiola Medeiros, Michael J Callahan, Elizabeth O Garner, Robert W Gordon, Chandler Birch,[...]. Am J Surg Pathol 2007
702
50

BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.
Ang Li, Rong Xie, Qihuan Zhi, Yixiao Deng, Yangming Wu, Weiwei Li, Lu Yang, Zinan Jiao, Jiaqi Luo, Yi Zi,[...]. Gynecol Oncol 2018
17
50

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Harvey A Risch, John R McLaughlin, David E C Cole, Barry Rosen, Linda Bradley, Isabel Fan, James Tang, Song Li, Shiyu Zhang, Patricia A Shaw,[...]. J Natl Cancer Inst 2006
438
50

Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population.
M Sekine, H Nagata, S Tsuji, Y Hirai, S Fujimoto, M Hatae, I Kobayashi, T Fujii, I Nagata, K Ushijima,[...]. Clin Cancer Res 2001
59
50

ACS releases updated guidelines on cancer screening.
Mara Lambert. Am Fam Physician 2012
2
50

BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer.
Ikuko Sakamoto, Yosuke Hirotsu, Hiroshi Nakagomi, Hidetaka Ouchi, Atsushi Ikegami, Katsuhiro Teramoto, Kenji Amemiya, Hitoshi Mochizuki, Masao Omata. Cancer 2016
39
50

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
665
50

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Kathryn P Pennington, Tom Walsh, Maria I Harrell, Ming K Lee, Christopher C Pennil, Mara H Rendi, Anne Thornton, Barbara M Norquist, Silvia Casadei, Alexander S Nord,[...]. Clin Cancer Res 2014
484
50

Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.
Janice S Kwon, Anna Tinker, Gary Pansegrau, Jessica McAlpine, Melissa Housty, Mary McCullum, C Blake Gilks. Obstet Gynecol 2013
103
50

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Melinda L Telli, Kirsten M Timms, Julia Reid, Bryan Hennessy, Gordon B Mills, Kristin C Jensen, Zoltan Szallasi, William T Barry, Eric P Winer, Nadine M Tung,[...]. Clin Cancer Res 2016
307
50

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Mary B Daly, Tuya Pal, Michael P Berry, Saundra S Buys, Patricia Dickson, Susan M Domchek, Ahmed Elkhanany, Susan Friedman, Michael Goggins, Mollie L Hutton,[...]. J Natl Compr Canc Netw 2021
21
50

Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers.
Claudia Marchetti, Francesca De Felice, Innocenza Palaia, Giorgia Perniola, Angela Musella, Daniela Musio, Ludovico Muzii, Vincenzo Tombolini, Pierluigi Benedetti Panici. BMC Womens Health 2014
86
50

Whole-genome characterization of chemoresistant ovarian cancer.
Ann-Marie Patch, Elizabeth L Christie, Dariush Etemadmoghadam, Dale W Garsed, Joshy George, Sian Fereday, Katia Nones, Prue Cowin, Kathryn Alsop, Peter J Bailey,[...]. Nature 2015
715
50

Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.
B A M Heemskerk-Gerritsen, C Seynaeve, C J van Asperen, M G E M Ausems, J M Collée, H C van Doorn, E B Gomez Garcia, C M Kets, F E van Leeuwen, H E J Meijers-Heijboer,[...]. J Natl Cancer Inst 2015
113
50

Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer.
Akira Hirasawa, Issei Imoto, Takuya Naruto, Tomoko Akahane, Wataru Yamagami, Hiroyuki Nomura, Kiyoshi Masuda, Nobuyuki Susumu, Hitoshi Tsuda, Daisuke Aoki. Oncotarget 2017
18
50

Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study.
Yakir Segev, Barry Rosen, Jan Lubinski, Jacek Gronwald, Henry T Lynch, Pal Moller, Charmaine Kim-Sing, Parviz Ghadirian, Beth Karlan, Charis Eng,[...]. Fam Cancer 2015
19
50

Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.
Catherine A Shu, Malcolm C Pike, Anjali R Jotwani, Tara M Friebel, Robert A Soslow, Douglas A Levine, Katherine L Nathanson, Jason A Konner, Angela G Arnold, Faina Bogomolniy,[...]. JAMA Oncol 2016
109
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.